Disease activity in and quality of life of patients with psoriatic arthritis mutilans : the Nordic PAM Study by Lindqvist, U. et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=irhe20
Download by: [University of Helsinki] Date: 20 December 2017, At: 00:56
Scandinavian Journal of Rheumatology
ISSN: 0300-9742 (Print) 1502-7732 (Online) Journal homepage: http://www.tandfonline.com/loi/irhe20
Disease activity in and quality of life of patients
with psoriatic arthritis mutilans: the Nordic PAM
Study
U Lindqvist, B Gudbjornsson, L Iversen, L Laasonen, L Ejstrup, T Ternowitz &
M Ståhle
To cite this article: U Lindqvist, B Gudbjornsson, L Iversen, L Laasonen, L Ejstrup, T Ternowitz
& M Ståhle (2017) Disease activity in and quality of life of patients with psoriatic arthritis
mutilans: the Nordic PAM Study, Scandinavian Journal of Rheumatology, 46:6, 454-460, DOI:
10.1080/03009742.2017.1278787
To link to this article:  https://doi.org/10.1080/03009742.2017.1278787
© 2017 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
Published online: 10 Feb 2017.
Submit your article to this journal 
Article views: 496
View related articles 
View Crossmark data
Disease activity in and quality of life of patientswith psoriatic arthritis mutilans:
the Nordic PAM Study
U Lindqvist1, B Gudbjornsson2, L Iversen3, L Laasonen4, L Ejstrup5, T Ternowitz6, M Ståhle7
1Department of Medical Sciences, Uppsala University, Uppsala, Sweden
2Centre for Rheumatology Research, University Hospital and Faculty of Medicine, University of Iceland, Reykjavik, Iceland
3Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark
4Helsinki Medical Imaging Center, Helsinki University Central Hospital, Helsinki, Finland
5Department of Rheumatology, Odense University Hospital, Odense, Denmark
6Department of Dermatology, Stavanger University Hospital, Stavanger, Norway
7Dermatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Objective: To describe the social status and health-related quality of life of patients with psoriatic arthritis mutilans
(PAM) in the Nordic countries.
Method: Patients with at least one mutilated joint conﬁrmed by radiology were studied. Disease activity involving
joints and skin, physician-assessed disease activity, and patient’s education and work status were recorded. Data from
the 36-item Short Form Health Survey, Health Assessment Questionnaire and Dermatology Life Quality Index
questionnaire were gathered and correlated with disease duration, pain, and general well-being (visual analogue
scale). The controls were 58 Swedish patients with long-standing psoriatic arthritis sine PAM.
Results: Sixty-seven patients were included. Patients with PAM had a protracted disease history (33 ± 14 years) and
disease onset at a relatively early age (30 ± 12 years). Overall inﬂammatory activity at inclusion was mild to moderate.
The mean number of mutilated joints was 8.2 and gross deformity was found in 16% of patients. Forty per cent were
treated with biological and 32% with conventional synthetic disease-modifying anti-rheumatic drugs. Forty-two per
cent had retired early or were on sick leave. Impaired functional capacity with little or no ability to perform self-care or
everyday tasks was reported by 21% of the patients. Patients between 45 and 60 years of age reported the most impaired
quality of life in comparison to the control group.
Conclusion: PAM seriously affects social functioning. Whether early recognition of PAM and new forms of therapy
can improve disease outcome and quality of life remains to be studied.
Psoriatic arthritis (PsA) is the most common arthritic
condition associated with psoriasis (1). The true preva-
lence of PsA in the general population is not fully clear,
but is reported to be 0.13–0.25% in the Nordic countries
(2–5). By applying classiﬁcation criteria for psoriatic
arthritis [ClASsiﬁcation criteria for Psoriatic ARthritis
(CASPAR) study] (6), the prevalence of PsA in psoriasis
patients was estimated to be 13.8% (1), while other
studies report a higher prevalence of 27–30% (7–9).
Joint and muscle symptoms have been self-reported by
up to one-third of psoriatic patients (10).
PsA can present in a variety of forms, both in individual
patients and between patients (2). Initially, Moll and Wright
described ﬁve major forms of PsA, with psoriatic arthritis
mutilans (PAM) being the most severe and rarest phenotype
(11). Subsequent categorization of PsA suggested subdivi-
sion into two main groups, with or without axial involve-
ment (12), where coexisting polyarthritis predicted an
unfavourable outcome (13). The most deforming variant of
PsA is PAM, with a prevalence of about 5% according to
Moll and Wright (11), even though this phenotype seems
rare nowadays (14). Nevertheless, the prevalence of PAM in
one cohort of established PsA was reported to reach 21%
(15). In an early Swedish PsA cohort (n = 334) with a
10 year follow-up, none of the patients developed PAM
(16, personal communication T Husmark, 2014). In our
recent epidemiological study in the Nordic population, the
prevalence of PAM was found to be only 3.9 per million
inhabitants (14). Occasionally, arthritis mutilans can also be
associated with other severe arthritic diseases, e.g. rheuma-
toid arthritis (17). As there are no established classiﬁcation
criteria to deﬁne PAM, the Group for Assessment of
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Psoriasis and Psoriatic Arthritis (GRAPPA) has taken the
initiative to develop a consensus deﬁnition of PAM (18).
We describe here the phenotype of Nordic patients
with PAM, and focus on the effects on daily life and
social activities in comparison with patients with long-
standing PsA but without mutilating disease.
Method
We have previously reported inclusion and exclusion
criteria for the Nordic PAM Study, as well as demo-
graphics and disease settings in 59 patients with PAM
(14). The objectives of the present study are to report the
quality of life of PAM sufferers in the Nordic countries,
and to describe effects of the disease on functional
capacity and social life. We have added eight new
patients to the 59 previously reported; four from Den-
mark, three from Sweden, and one from Norway. Thus,
the present study included 67 PAM patients.
A group of 58 patients with PsA sine PAM, with
long-standing disease, using data from a 5 year follow-
up, served as controls (19).
Clinical examination and questionnaires
All patients underwent detailed dermatological and rheu-
matological clinical evaluation as previously described
(14). In addition, the patients answered three standardized
questionnaires: the modiﬁed Health Assessment Ques-
tionnaire (mHAQ or HAQ) (20, 21), the Health-related
quality of life 36-item Short Form Health Survey (SF-36)
(22, 23), and the Dermatology Life Quality Index (DLQI)
questionnaire (24, 25). Self-reported demographic data on
education, work, and marital status were also registered.
The HAQ includes questions associated with assistance
necessitated by functional incapacity, consisting of 20
items (20, 21), and results in disability indices for eight
categories: dressing and grooming, rising, eating, walking,
hygiene, reach, grip strength, and extramural activities.
The SF-36 gives results on eight speciﬁc scales (22,
23): physical functioning, physical role, bodily pain,
general health, vitality, social interactivity, emotional
role, and mental health.
The DLQI (24, 25) comprises 10 questions concerning
symptoms and feelings, daily activities, leisure, work,
school, personal relationships, and treatment. Each ques-
tion is answered by marking a tick box: ‘not at all’, ‘a
little’, ‘a lot’, or ‘very much’, and is scored from 0 to 3.
The scores are summed, giving a range from 0 (no impair-
ment of quality of life) to 30 (maximum impairment).
Data analysis
All patient data were coded and analysed using the
Microsoft Excel for Mac 2011 and GraphPad Prism
version 6.0 statistical software packages. The χ2 and
t-tests were used to compare dichotomous values
and means, respectively. We calculated 95% conﬁdence
intervals (CIs) for prevalence rates using the binomial
distribution. All reported p-values are based on two-
tailed analysis.
To assess the association between PAM and disease
expression, we performed logistic regression analysis
using the independent variables skin/joint age at onset,
skin/joint disease duration, minimum disease activity
(MDA) score (0–7), and number of swollen joints and
tender joints (grouped into 1–4 vs 0 and ≥ 5 vs 0). We
estimated univariable models followed by four multi-
variable models. In the ﬁrst model, we included skin
disease age at onset and skin disease duration, and in
the second model joint disease age at onset and joint
disease duration. In the third model, we included the
variables which had a signiﬁcant association with PAM
in model 1 or 2. Finally, we estimated a model including
the signiﬁcant variables in model 3, MDA score, and the
number of swollen and tender joints.
To investigate the risk of a high HAQ score
(HAQ > 1), univariable logistic regression models were
estimated including the independent variables PAM,
erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), global assessment of disease activity visual ana-
logue scale (VAS), assessment of pain VAS, skin/joint
age at onset, skin/joint disease duration, MDA score,
number of swollen joints, and number of tender joints.
Furthermore, the variables signiﬁcantly associated with
high HAQ score in the univariate analyses were included
in a multivariable model.
Ethical issues
Written informed consent was obtained from all study
participants. The bioethics Committee and Data Protec-
tion Authorities in all four countries approved the study
protocol.
Results
Demographics and disease activity
Demographic data and disease activity of 67 patients with
PAM compared to 58 individuals in the reference group are
presented in Tables 1 and 2. At inclusion,MDAwas present
in 11 (19%) of the reference patients compared with 14
(25%) of the PAM patients (difference not signiﬁcant).
Patients’ assessments of disease activity and of pain corre-
lated signiﬁcantly with the physician’s assessment of arthri-
tis (r = 0.577, p < 0.0001; r = 0.560, p < 0.0001), while there
was no correlation between skin and joint disease activity,
by either patients’ or physicians’ estimates.
Forty-two per cent of patients had attended elementary
school and 24% high school, and 34% had a college
education (47% of the women and 19% of the men).
Altogether, 48% of PAM patients were retired or on sick
leave. Thirty-eight per cent lived in a house and received
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regular or occasional help, but themajority (61%)managed
daily activities without additional assistance. Most of the
patients (78%) had full or nearly full functional capacity,
according to the physician’s assessment, while 21% had
restricted functional capacity with scarcely any ability to
perform self-care or everyday tasks. Only one patient was
incapable of any self-care. There was no signiﬁcant differ-
ence between men and women in this respect.
Quality of life
The overall estimated HAQ score was 0.98 ± 0.81,
with no signiﬁcant differences between countries or
gender. Dressing, gripping, and opening tins and jars
proved difﬁcult and required help for several patients
(Figure 1).
Four out of eight SF-36 subscales, i.e. physical func-
tion, physical role, bodily pain, and general health, were
somewhat impaired compared to those of a healthy adult
reference population (Figure 2). Physical function and
physical role were most impaired in 45–60-year-olds, of
both genders, and thus deteriorated with advancing age
(data not shown).
Regarding the skin disease, which was mild in the
majority of patients, only a minor deterioration in DLQI
was recorded, with no gender difference (Table 2).
Table 1. Demographics of 67 patients with psoriatic arthritis mutilans (PAM) in comparison to 58 patients with psoriatic arthritis
(PsA) sine PAM.
PAM patients
(n = 67)
Reference PsA
(n = 58) p
Gender, female/male, n 33/34 28/30 ns
Age (years) 58 ± 11 56 ± 14 ns
Age at onset of psoriasis (years) 25 ± 15 32 ± 18 < 0.05
Age at onset of PsA (years) 30 ± 12 42 ± 13 < 0.001
Disease duration psoriasis (years) 33 ± 14 21 ± 14 < 0.001
Disease duration PsA(years) 28 ± 12 14 ± 8.2 < 0.001
Treatment at inclusion, n on bDMARD/csDMARD/both 9/24/19 2/29/2 –
Data are shown as mean ± sd unless otherwise indicated.
n, number of individuals; ns, non-signiﬁcant difference; bDMARD, biological disease-modifying anti-rheumatic drug; csDMARD,
conventional systemic disease-modifying anti-rheumatic drug.
Table 2. Disease activity and quality of life in 67 patients with psoriatic arthritis mutilans (PAM) in comparison to 58 patients with
psoriatic arthritis (PsA) sine PAM.
PAM patients
(n = 67)
Reference PsA
(n = 58) p
ESR (mm/h) 17.6 ± 18.4 13.9 ± 15.0 ns
CRP (mg/L) 9.1 ± 19.2 12.9 ± 14.2 ns
Assessment of pain VAS (mm) 30.3 ± 26.1 37.3 ± 21.8 ns
Global assessment of disease activity VAS (mm) 33.3 ± 26.0 36.2 ± 22.4 ns
HAQ 0.98 ± 0.81 0.56 ± 0.45 0.001
DLQI 3.7 ± 4.1 nk –
Morning stiffness (min) 40 ± 43 nk –
No. of swollen joints (66) 2.0 ± 3.4 3.6 ± 5.0 0.043
No. of tender joints (68) 5.3 ± 9.1 2.6 ± 3.8 0.032
Dactylitis, n (%) 41 (68) nk –
PASI 4.5 ± 5.5 6.6 ± 9.0 ns
DAS28 3.4 ± 1.1 3.2 ± 1.1 ns
DAPSA 15.7 ± 15.4 14.8 ± 8.6 ns
Physician’s global assessment of:
Arthritis (mm) 24.3 ± 19.7 nk –
Skin activity (mm) 17.4 ± 19.7 nk –
Psoriasis (n)
Clear or almost clear/Mild or mild to moderate/Moderate to severe
28/25/10 nk –
Functional capacity ACR (n)
High/Moderate/Low/None
8/35/11/1 nk –
Data are shown as mean ± sd unless otherwise indicated.
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; VAS, visual analogue scale; HAQ, Health Assessment Questionnaire;
DLQI, Dermatology Quality of Life Index; PASI, Psoriasis Area Severity Index; DAS28, 28-joint Disease Activity Score; DAPSA, Disease
Activity in Psoriatic Arthritis; ACR, American College of Rheumatology; ns, non-signiﬁcant difference; nk, not known.
456 U Lindqvist et al
www.scandjrheumatol.dk
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 H
els
ink
i] 
at 
00
:56
 20
 D
ec
em
be
r 2
01
7 
Comparison between quality of life and disease activity
Functional capacity, measured as HAQ score, correlated
with ESR (r = 0.558, p < 0.0001), Disease Activity
Score based on 28-joint count (DAS28)-CRP
(r = 0.566, p = 0.0004), and Disease Activity in Psoriatic
Arthritis (DAPSA) (r = 0.445, p = 0.0051). The HAQ
score was independent of treatment with anti-tumour
necrosis factor-α (anti-TNF-α) treatment.
The mental component summary and physical com-
ponent summary on the SF-36 scale were correlated with
the total number of deformed joints (r = −0.521,
p = 0.0028; r = −0.362, p = 0.0455). The physical
component summary was also correlated with ESR
(r = −0.424, p = 0.0011). Patients treated with anti-
TNF-α had a worse physical role (p = 0.05) and poorer
mental health (p = 0.05) on the SF-36 scale compared to
untreated PAM-patients.
Psoriatic arthritis mutilans versus reference group
Patients with long-standing PsA, chosen as the reference
for PAM, and matched for age and gender, revealed
signiﬁcantly different demographic data for the onset
and duration of PsA and psoriasis (Table 1). Patients
with PAM had fewer swollen joints (2.0 ± 3.4 vs
3.6 ± 5.0, p = 0.043) but signiﬁcantly more tender joints
(5.3 ± 9.1 vs 2.6 ± 3.8 p = 0.032) compared to the
reference group. Also, functional capacity, measured as
HAQ score, was deteriorated compared to the reference
group (0.98 ± 0.81 vs 0.56 ± 0.45, p = 0.001).
In logistic regression models including duration
and age at onset, only duration was signiﬁcantly
associated with PAM (Table 3). Furthermore, in a
model including duration of both skin and joint dis-
ease, only duration of joint disease was signiﬁcantly
associated with PAM (OR 1.14, 95% CI 1.07–1.21;
p < 0.001). MDA, and the number of swollen and
tender joints did not inﬂuence the association between
the duration of joint disease (adjusted OR 1.19, 95%
CI 1.11–1.28; p < 0.001) and PAM, although a high
number (≥ 5 vs 0) of tender joints was signiﬁcantly
associated with PAM (adjusted OR 6.16, 95% CI
1.21–31.29; p = 0.028).
HAQ score was signiﬁcantly associated with PAM,
global assessment of disease activity VAS, assessment of
pain VAS, disease duration of arthritis, and ESR in the
univariate analysis (Table 4). In the multivariable model,
including the four signiﬁcant predictors, only PAM (OR
6.99 95% CI 1.63–29.92; p < 0.009) and disease activity
VAS remained signiﬁcantly associated with HAQ score
(OR 1.05, 95% CI 1.01–1.09; p = 0.026).
Discussion
The main purpose of the present study was to describe the
expression of PAM and the effects of the disease on
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Figure 1. Need for (A) daily help and (B, C) aids for 67 patients with
psoriatic arthritis mutilans. HAQ, Health Assessment Questionnaire.
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health-related quality of life. At study inclusion, a mean
disease duration of three decades was present and thus we
have been studying the effects of a long disease history.
PAM patients in the present study had a long duration
of PsA and were young at disease onset, with a mean age
of 30 years, compared with our reference group and a
Swedish cohort of individuals with early PsA, the
SwePsA, with a mean age of 47 years at onset (16). In
the SwePsA, the patients were followed prospectively and
a current subanalysis of data shows that the mean age at
onset of polyarthritic PsA disease was 43 years for men
and 52 years for women (personal communication T Hus-
mark, 2014). So far, no PAM has been identiﬁed in this
cohort, which has a mean follow-up of 10 years at the
time of writing. In a literature review of 38 studies on PsA
comprising 18 768 patients, the mean age at onset of PsA
was 49 years (26). The age at onset of PAM is comparable
to that of spondylarthropathies with axial involvement
(27). Moreover, spinal involvement has been associated
with PAM, e.g. in the CASPAR study (28). PsA patients
with human leucocyte antigen (HLA) B*27, DQ B1*02,
and killer-cell immunoglobulin-like receptor (KIR) gene
3DS1 run an increased risk of developing PAM (29).
Furthermore, patients with HLA B*27 have an earlier
onset of disease and shorter interval between onset of
psoriasis and PsA (30). Thus, early age at onset, and
long duration of disease, would appear to be an important
predictor for the development of PAM, probably includ-
ing disease activity as well as outcome, and seems to be
closely related to other spondylarthropathies. Ta
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The age at onset of psoriasis usually ranges from child-
hood to adulthood, with three peaks: in early adolescence,
at about 30 years, and at 50 years (31). In the Stockholm
Psoriasis cohort, recruiting individuals >15 years old
within a year of disease onset, the mean age at onset
was 41 years, but ranged from 15 to 84 years, with two
distinct peaks: before and after 40 years of age (32).
In the present PAM cohort, disease activity measures,
except for tender joints, were low to moderate with no
signiﬁcant differences compared with the reference
group. The effect of long-standing PAM disease and a
substantial interindividual variation are possible confoun-
ders on our results. Having more than ﬁve tender joints is
of importance. This is an expression of long-standing
disease, not on an inﬂammatory basis, but rather as an
indicator of mutilated or severely damaged joints.
The patients’ standard of education was similar to that
of the general population in the Nordic countries, i.e.
college (tertiary) level in about one-third of the patients
(33). Most of the college graduates were women. The
loss of productivity was substantial for PAM patients.
Forty per cent had retired early and another 10% were
partly retired at inclusion in the study, compared with
the general population in the Nordic countries, where a
mean of 17% were pensioners (2008) in the age group
55–59 years (33). Despite having a good level of educa-
tion, the economic status of the patients must have been
affected by the loss of lifetime income and by the
increased costs of necessary regular help and of medical
service and treatment.
There are no speciﬁc instruments to assess health-
related quality of life in PAM. We have focused on the
HAQ to assess the effect of impairment, by disease-
caused deformity, on physical function. An important
ﬁnding was that the odds of having an HAQ score > 1
was higher in the PAM group than in the reference group
(PAM: OR 6.99, 95% CI 1.63–29.92; p = 0.009). How-
ever, the mean assessed HAQ score was not higher than
estimates of HAQ score in early untreated PsA or rheu-
matoid arthritis (34). Earlier studies have shown that the
burden of PsA, estimated as actively inﬂamed joints and
the number of clinically deformed joints, is positively
related to the HAQ score, but decreases with the duration
of the arthritic condition (35). As the reference group had
a signiﬁcantly shorter disease duration than the PAM
group, it could be surmised that the real difference in
function between PAM and the reference group may be
even more pronounced than observed herein. Rodriguez-
Moreno et al reported reduced functional capacity in
PAM, estimated by HAQ, and functional status according
to American College of Rheumatology criteria, being
affected primarily by disease duration and distal interpha-
langeal involvement (36).
Another important ﬁnding was that the HAQ score
was inﬂuenced by patients’ assessment of global disease
activity. The level of function, estimated as HAQ score,
was a direct assessment of patients’ ability to use their
hands, with the need for help in dressing, gripping, and
opening tins and jars, and these factors are predestined to
affect patients’ global assessment of disease.
The SF-36, being a generic health assessment ques-
tionnaire, is not speciﬁc for PsA. SF-36 identiﬁes mental
as well as physical components. It is reportedly respon-
sive to short-term changes, but not to disease progres-
sion. In PAM, SF-36 could further visualize the effect of
the disease on patients’ function – and expectation of
function – and thus of general health. The implication of
reduced function was most prominent in the middle-aged
group and declined with age.
Conclusion
In summary, we present a large series of patients from
the Nordic PAM Study where the most pronounced
attributes were duration of disease, number of tender
joints, and reduced functional capacity measured by the
HAQ. PAM causes loss of work ability and a need for
help with everyday activities. The foremost outcome was
the early retirement of patients suffering from PAM.
Table 4. Logistic regression HAQ_D50 = 1 if Health Assessment Questionnaire (HAQ) score > 1: reference group = 0 and psoriatic
arthritis mutilans (PAM) = 1.
Variable
Crude
OR (95% CI), p
Multivariable
OR (95% CI), p
PAM vs reference 7.57 (2.65–21.65), < 0.001 6.99 (1.63–29.92), 0.009
Global assessment of disease activity VAS 1.04 (1.02–1.06), < 0.001 1.05 (1.01–1.09), 0.026
Assessment of pain VAS 1.03 (1.01–1.04), 0.007 1.00 (0.96–1.04), 0.982
Disease duration PsA 1.06 (1.02–1.10), 0.002 1.02 (0.97–1.08), 0.379
Disease duration psoriasis 1.02 (0.99–1.05), 0.182
No. of tender joints, grouped 1–4 vs 0 1.01 (0.37–2.80), 0.981
No. of tender joints, grouped ≥ 5 vs 0 2.00 (0.70–5.68), 0.193
No. of swollen joints, grouped 1–4 vs 0 1.06 (0.41–2.76), 0.907
No. of swollen joints, grouped ≥ 5 vs 0 1.43 (0.47–4.37), 0.528
ln CRP 1.14 (0.77–1.68), 0.502
ESR 1.04 (1.01–1.07), 0.007 1.03 (0.99–1.07), 0.106
VAS, visual analogue scale; PsA, psoriatic arthritis; ln, logarithmic; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate;
OR, odds ratio; CI, conﬁdence interval.
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